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Isoprenoids are synthesized by consecutive condensations of theirˆve-carbon precursor, isopentenyl diphosphate, to its isomer, dimethylallyl diphosphate. Two pathways for these precursors are known. One is the mevalonate pathway, which operates in eucaryotes, archaebacteria, and cytosols of higher plants. The other is a recently discovered pathway, the nonmevalonate pathway, which is used by many eubacteria, green algae, and chloroplasts of higher plants. To In 1956, a newly discovered acetate-replacing factor for Lactobacilli was identiˆed as b-hydroxyb-methyl-d-valerolactone by Wolf et al. 1) This compound also was found to be a precursor of cholesterol. 2) In the same year, the chemical structure of``hiochic acid'', a growth factor for Lactobacillus homohiochi and L. heterohiochi, also was identiˆed as b-hydroxy-b-methyl-d-valerolactone by Tamura, 3) who showed that sake (Japanese rice wine) frequently is spoiled by the bacteria that contain this growth factor. Later, b-hydroxy-b-methyl-d-valerolactone and``hiochic acid'' were renamed mevalonate as their standard name.
In the 1960s, Bloch and Lynen identiˆed the mevalonate pathway for cholesterol biosynthesis. 4, 5) In this pathway, three molecules of acetyl-CoA condense successively to form 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) (Fig. 1 ). This CoAderivative is reduced to mevalonate by HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway in humans. Its speciˆc inhibitors, pravastatin and related compounds, are widely used as cholesterol-lowering agents. 6) Mevalonate is then phosphorylated twice and decarboxylated to form isopentenyl diphosphate (IPP). IPP is then converted to its isomer, dimethylallyl diphosphate (DMAPP), catalyzed by IPP isomerase. IPP and DMAPP synthesized in the mevalonate pathway are used as basic units in the biosynthesis of isoprenoids such as sterols, carotenoids, and dolichols.
Since the discovery of the mevalonate pathway, it was widely accepted that IPP and DMAPP were formed only through this pathway in all living organisms. However, several results inconsistent with the operation of the mevalonate pathway in certain bacteria had been reported. For example, [ 13 C]acetate, a precursor of the mevalonate pathway, was not incorporated into ubiquinone of Escherichia coli 7) or into pentalenolactone produced by Streptomyces chromofuscus (H. Seto, unpublished results). 8, 9) Feeding experiments with [U- 13 C]glucose and pentalenolactone-producing S. exfoliatus showed labeling patterns inconsistent with the mevalonate pathway. 8, 9) Furthermore, mevinolin, a speciˆc inhibitor of HMG-CoA reductase, did not inhibit the growth of E. coli. 7) These results suggested the existence of an alternative pathway for isoprenoid biosynthesis, which was not identiˆed for some time.
In 1996, Rohmer discovered theˆrst reaction step of the alternative, nonmevalonate, pathway for the formation of IPP and DMAPP in E. coli.
10) My group was encouraged by this pioneering work and began to study the nonmevalonate pathway. This review centers mostly on our studies of this alternative pathway. In this pathway, three molecules of acetyl-CoA condense successively to form HMG-CoA. This CoA-derivative is reduced to mevalonate by HMG-CoA reductase, the rate-limiting enzyme of this pathway. Mevalonate is then phosphorylated twice and decarboxylated to form the isoprene unit, IPP. This unit is then converted to DMAPP, with catalysis by IPP isomerase. HMGCoA, 3-hydroxy-3-methylglutaryl coenzyme A; IPP, isopentenyl diphosphate; DMAPP, dimethylallyl diphosphate.
(DXP) by the condensation of pyruvate and D-glyceraldehyde 3-phosphate, catalyzed by DXP synthase (Fig. 2) .
10) The dxs gene encoding this enzyme waŝ rst cloned from E. coli. 11, 12) This enzyme has a typical thiamine-binding motif and needs both thiamine and a divalent cation such as Mg 2+ or Mn 2+ for enzyme activity. The reaction preceding this condensation had earlier been found by Yokota et al. 13, 14) They detected the formation of 1-deoxy-D-xylulose (DX) from pyruvate and D-glyceraldehyde by pyruvate dehydrogenase of E. coli or Bacillus subtilis.
We cloned a dxs gene homolog from Streptomyces sp. strain CL190 by the polymerase chain reaction using oligonucleotide primers based on highly conserved amino acid sequences and compared its enzymatic properties with those of the E. coli DXP synthase. 15 ) Although these two enzymes had diŠerent origins, they had almost identical enzymatic properties.
Le áon and co-workers isolated albino mutants of Arabidopsis thaliana. The albino phenotype of one of these mutants was restored by the feeding of DX, the free alcohol of DXP. 16) This mutant had a mutation in the cla1 gene, which coded for an amino acid sequence very similar to that of E. coli DXP synthase. The cla1 gene transcript and its protein accumulated in young developing tissues.
DXP is a biosynthetic intermediate not only for IPP and DMAPP but also for thiamine and pyridoxol in E. coli (Fig. 2) . 17) Thisˆnding means that DXP synthase is not the only enzyme speciˆc for the nonmevalonate pathway.
2. Second reaction step, catalyzed by DXP reductoisomerase (EC 1.1.1.267)
Rohmer and co-workers found that 2-Cmethylerythritol (ME) was incorporated into E. coli cells, which used it as the precursor of the side chain of ubiquinone ( Fig. 3(A) ). 18, 19) Because of thisˆnd-ing, the intramolecular rearrangement of DXP had been assumed to yield a hypothetical rearrangement product, 2-C-methylerythrose 4-phosphate, which was then converted to 2-C-methyl-D-erythritol 4-phosphate (MEP) by an unknown reduction process ( Fig. 3(A) ). For this reason, it was assumed that two enzymes were involved in the formation of MEP from DXP.
To elucidate the details of this mechanism, we studied the cloning of the gene responsible for MEP synthesis. We used the strategy of screening for E. coli mutants with a metabolic block(s) between DXP and MEP. Such mutants would need MEP or ME for growth. In the screening, we used ME and were able to select ten mutants with the desired properties; the addition of ME, but not of DX, to the minimum medium facilitated the growth of the mutants. 20) By complementation of these mutants, only the yaeM gene, with an unknown function, was cloned. 21) All of the ten mutants that needed ME were conˆrmed to be yaeM-gene-deˆcient mutants.
Next, to check whether the yaeM gene was in fact Step of the Nonmevalonate Pathway. DXP synthase catalyzes the condensation of pyruvate and D-glyceraldehyde 3-phosphate to form DXP, the biosynthetic intermediate not only for IPP and DMAPP but also for thiamine and pydoxol. DX can be incorporated into E. coli and Arabidopsis thaliana to be used as the precursor of these compounds. TPP, thiamine diphosphate; DX, 1-deoxy-D-xylulose. (A) DXP reductoisomerase catalyzes simultaneous intramolecular rearrangement and reduction of DXP to form MEP, presumably via the hypothetical reaction intermediate, MEOP. FMM is a speciˆc inhibitor of this enzyme. ME can be incorporated into E. coli to be used as the precursor of IPP and DMAPP. (B) Ketol acid reductoisomerase in valine biosynthesis catalyzes the simultaneous intramolecular rearrangement and reduction of 2-acetolactate to form 2,3-dihydroxyisovalerate, presumably via a hypothetical reaction intermediate, 2-oxo-3-hydroxyisovalerate. This hypothetical compound inhibits ketol acid reductoisomerase activity. ME, 2-Cmethylerythritol; MEOP, 2-C-methylerythrose 4-phosphate; FMM, fosmidomycin.
responsible for MEP formation, we constructed a plasmid for the overexpression of the gene product. The puriˆed enzyme was detected as a homogeneous protein band with a subunit size of 42 kDa by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The enzyme had a molecular mass of 165 kDa as estimated by native polyacrylamide gel electrophoresis. The enzyme appeared to be a homotetramer.
Incubation of the enzyme with DXP in the presence of NADPH resulted in a decrease in the NADPH level, indicating that the enzyme converted DXP into an unknown reaction product. We puriˆed the reaction product and identiˆed it MEP on the basis of NMR and MS data. 20) The result showed that MEP is synthesized in the presence of NADPH by rearrangement and reduction of DXP in a single step (Fig. 3(A) ). We designated this enzyme DXP reductoisomerase and renamed the yaeM gene``dxr''. 21) The reaction preceding this biosynthetic rearrangement is involved in the biosynthesis of valine, isoleu- (Fig. 3(B) ). 22) It should be noted that 2-oxo-3-hydroxy isovalerate, a compound with a keto function, had been excluded as a possible reaction intermediate because of its inhibitory eŠect on this reaction. 22) As mentioned above, DXP is a precursor not only for IPP and DMAPP but also for thiamine and pyridoxol. Therefore, the reaction catalyzed by DXP reductoisomerase is the committed step in the nonmevalonate pathway.
We were theˆrst to identify the catalytic residues of DXP reductoisomerase by analysis of the E. coli yaeM-gene-deˆcient mutants described above. Glu 231 of the E. coli enzyme is important in the conversion of DXP to MEP, and His 153 , His 209 , and His 257 are part of DXP binding to the enzyme. 23) These results were supported by those of studies of the threedimensional structure of DXP reductoisomerase. 24) 3. Fosmidomycin, an inhibitor of DXP reductoisomerase DXP reductoisomerase is widely distributed in plants and many eubacteria including pathogenic ones, but not in mammals, so this enzyme could be a target for screening for herbicides and antibacterial drugs (Table 1) . 20, 21) For rapid screening for DXP reductoisomerase inhibitors, we constructed an assay system that used a microplate reader. 25) Before screening, we did a literature search to try toˆnd antibiotics active against E. coli and B. subtilis, which both have the nonmevalonate pathway, but inactive against Staphylococcus aureus, which has the mevalonate pathway; we thought that any inhibitors might have already been reported as antibiotics. Fosmidomycin (FR-31564) had the expected antibacterial spectrum and was identiˆed as a possible DXP reductoisomerase inhibitor. Fosmidomycin had antibacterial activity against most Gram-negative and some Gram-positive bacteria. 26, 27) Because it inhibited menaquinone and carotenoid biosynthesis in Micrococcus luteus, it was proposed that the antibiotic inhibited the biosynthesis of isoprenoids. 28) From these studies of fosmidomycin, we assumed that the antibiotic might inhibit DXP reductoisomerase.
In our assay, fosmidomycin strongly inhibited DXP reductoisomerase in a dose-dependent way with an IC 50 of 24 nM. The Lineweaver-Burk plot indicated competitive inhibition with a Ki value of 9.4 nM. Therefore, fosmidomycin was a competitive inhibitor of DXP reductoisomerase. 25) We next investigated the antibacterial activity of fosmidomycin against E. coli. Bacterial growth was completely inhibited at 6.25 mg W ml FMM. However, inhibition by the antibiotic of the growth of E. coli was suppressed by ME added to the growth medium. In addition, fosmidomycin had no eŠect on the growth of an E. coli DXP reductoisomerase disruptant 29) in the presence of ME. The lack of inhibition by fosmidomycin of the disruptant suggested that the disruptant lacked a molecular target. From these results, we concluded that fosmidomycin speciˆcally inhibited DXP reductoisomerase in the nonmevalonate pathway. 25) It should be emphasized that fosmidomycin and MEOP, the hypothetical rearrangement intermediate of DXP reductoisomerase, have close structural similarities: they have formyl and phosphonate (or phosphate) functions separated byˆve chemical bonds.
As mentioned earlier, the DXP reductoisomerase reaction presumably proceeds in a manner similar to the ketol acid reductoisomerase reaction. Interestingly, 2-oxo-3-hydroxyisovalerate, a compound with a keto function corresponding to MEOP, inhibits ketol acid reductoisomerase, 22) whichˆnding supports the observation that fosmidomycin inhibits DXP reductoisomerase as an analog of MEOP.
As I mentioned above, we identiˆed the catalytic residues of DXP reductoisomerase 23) and clariˆed its crystal structure. 24) These results should provide information useful in the development of antibacterial drugs and herbicides.
Reaction steps leading to synthesis of IPP from MEP
How many reaction steps are necessary for the conversion of MEP into IPP? At least three dehydrations and one phosphorylation process would be needed.
To elucidate the later reactions that lead to the synthesis of IPP from MEP, we cloned the genes responsible for conversion of MEP into IPP. To do this, we used E. coli mutants with a metabolic block(s) between MEP and IPP. Such a mutation would be lethal, so we engineered an E. coli transformant with an additional biosynthetic pathway for IPP: the mevalonate pathway. 30) This transformant with mevalonate kinase, phosphomevalonate kinase, and diphosphomevalonate decarboxylase activities can use part of the mevalonate pathway for IPP biosynthesis only in the presence of mevalonate. The genes encoding these enzymes were cloned from Streptomyces sp. strain CL190. 30, 31) Mevalonate added to the growth medium is converted by these three enzymes into IPP, which is then used by the transformant as a precursor for isoprenoids.
With this transformant as the parent strain, we obtained mutants with an obligatory requirement of mevalonate for growth. 32) These mutants had the expected phenotypes: the addition of mevalonate, but not ME, to a minimum medium facilitated the growth of the mutants. These phenotypic features showed unequivocally that the mutants had a defect(s) in the pathway leading to IPP from MEP. Using these mutants, we cloned four uncharacterized genes, ygbP, ychB, ygbB, gcpE, that complemented the defects of these blocked mutants in synthesizing IPP from MEP (Table 1) . [32] [33] [34] It should be noted that these four genes apparently are needed for IPP biosynthesis in E. coli. The distribution patterns of the DXP synthase and DXP reductoisomerase genes of the nonmevalonate pathway in eubacteria were similar (Table 1) , supporting the hypothesis that these four genes are essential for this pathway.
To identify the functions of the gene products of gcpE, ygbB, ychB, and ygbP genes, we constructed plasmids for overexpression of the gene products and could prepare enough of the enzymes to characterize them. Next, we sought to select appropriate reaction conditions for the conversion of MEP into an unknown product by the action of one of the four enzymes.
4.1. Third reaction step, catalyzed by MEP cytidylyltransferase (EC 2.7.7.60)
The ygbP gene product converted MEP into an unknown reaction product in the presence of CTP. We puriˆed the reaction product and identiˆed it as 4-(cytidine 5?-diphospho)-2-C-methyl-D-erythritol 
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T. KUZUYAMA (CDP-ME) on the basis of the results of NMR and MS. 32) The results showed that MEP is converted to CDP-ME in the presence of CTP by the ygbP gene product, and that the gene product is essential for IPP biosynthesis (Fig. 4) . 32) We designated the enzyme MEP cytidylyltransferase and renamed the ygbP gene``mect''. 32) 4.2. Fourth reaction step, catalyzed by CDP-ME kinase (EC 2.7.1.148)
The ychB gene product converted CDP-ME to an unknown reaction product in the presence of ATP. We puriˆed the reaction product and identiˆed it as 2-phospho-4-(cytidine 5?-diphospho)-2-C-methyl-Derythritol (CDP-ME2P). 33) This result showed that CDP-ME is converted to CDP-ME2P in the presence of ATP by the ychB gene product, and that this gene product is essential for IPP biosynthesis (Fig. 4) . 33) We designated the enzyme 4-(cytidine 5?-diphospho)-2-C-methyl-D-erythritol kinase and renamed the ychB gene``cmek''. 33) 4.3. Fifth reaction step, catalyzed by MECDP synthase (EC 4.6.1.12)
The ygbB gene product converted CDP-ME2P to an unknown reaction product. We puriˆed the reaction product and identiˆed it as 2-C-methyl-Derythritol 2,4-cyclodiphosphate (MECDP).
34) The formation of MECDP was concomitant with the elimination of CMP from CDP-ME2P. This result showed that CDP-ME2P is converted to MECDP by the ygbB gene product, and that this gene product is essential for IPP biosynthesis (Fig. 4) . 34) We designated this enzyme MECDP synthase and renamed the ygbB gene``mecs''. 34) MECDP accumulates in some bacteria, including Corynebacterium ammoniagenes, under oxidative stress caused by benzyl viologen, 35) but there have been no reports on the role of MECDP in the nonmevalonate pathway. We showed that MECDP is an intermediate in the nonmevalonate pathway for IPP biosynthesis.
Independent of our studies, German researchers found that MECDP is synthesized from MEP by the consecutive actions of the ygbP, ychB, and ygbB gene products [36] [37] [38] and that MECDP is e‹ciently converted into phytoene in chromoplasts of Capsicum annuum and Narcissus pseudonarcissus.
39)
4.4. Function of the gcpE gene product Next, we incubated MECDP with the gcpE gene product in the presence of various possible cofactors such as NADPH, nucleotide triphosphates, or vitamins with the expectation that the gene product would convert MECDP to an unidentiˆed reaction product. However, attempts to detect this reaction product in vitro have been unsuccessful. An unidentied gene(s) could be involved in the use of MECDP as a substrate.
Recent studies
Recently, studies that used the IPP isomerasedisruptant of E. coli conˆrmed that IPP isomerase is not essential for growth. 40) Thisˆnding indicates that IPP and DMAPP are synthesized through independent routes in the late steps of the nonmevalonate pathway.
The lytB gene has a distribution pattern similar to the patterns of the dxs, dxr, ygbP, ychB, ygbB, and gcpE genes of the nonmevalonate pathway in eubacteria, suggesting that the lytB gene is involved in the nonmevalonate pathway. Although studies of the mutated lytB gene supported this suggestion, 41) the in vitro function of this gene product has not been elucidated.
Very recently, Jomaa et al. reported that the lytBdisruptant of E. coli accumulates 1-hydroxy-2-methyl-2-( E )-butenyl 4-diphosphate (HMBDP). 42) Arigoni and co-workers demonstrated that a recombinant E. coli that overexpresses the xylB, 43) dxr, ygbP, ychB, ygbB, and gcpE genes can convert exogenous DX into HMBDP. 44) In addition, they found that a recombinant E. coli overexpressing the xylB, dxr, ygbP, ychB, ygbB, gcpE, and lytB genes can convert exogenous DX into IPP and DMAPP. 45) In these experiments, the xylB gene product catalyzes the phosphorylation of DX to yield DXP in vivo. 43) These recentˆndings suggest that MECDP can be converted to HMBDP as catalyzed by the gcpE gene product and that HMBDP can be converted to IPP and DMAPP, catalyzed by the lytB gene product (Fig. 4) . However, the in vitro reactions catalyzed by the gcpE and lytB gene products have not been detected.
Conclusions
Theˆve reactions leading to the synthesis of MECDP from pyruvate and D-glyceraldehyde 3-phosphate of the nonmevalonate pathway elucidated to date are shown in Fig. 4 . The genes encoding the enzymes that catalyze theseˆve reactions have been cloned and characterized. Recently, EC numbers of these enzymes were assigned by the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (NC-IUBMB) and are available at http: W W www.chem.qmw.ac.uk W iubmb W enzyme W reaction W terp W nonMVA.html. The in vitro reactions leading to the synthesis of IPP and DMAPP from MECDP remain to be elucidated.
The nonmevalonate pathway is absent in mammals, but in many pathogenic bacteria, 21) plants, 21) and malaria parasites, 46) this pathway is essential for survival and growth. Therefore, the enzymes in the nonmevalonate pathway could be targets for screening for antibacterial drugs, herbicides, and antimalarial drugs. Screening for nonmevalonatepathway-speciˆc inhibitors is in progress in our laboratory.
